Want to join the conversation?
Biopharmaceutical company $REGN, along with Sanofi, said UnitedHealth Group will provide preferred access to Praluent Injection through OptumRx and UnitedHealthcare for commercial, Medicare, and Managed Medicaid patients. This will provide access to flexible dosing with Praluent on formularies covering more than 100MM patients in the US.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?